Biostatistician

Population Health Sciences Institute

Biography

Contact

Email: michael.cole@ncl.ac.uk
Telephone: +44 (0) 191 208 4587
Address: Population Health Sciences Institute, Baddiley-Clark Building, Richardson Road, Newcastle upon Tyne NE2 4AX, UK

Publications

Quickly discover relevant content by filtering publications.

Siebert S, Pratt AG, Stocken DD, Morton M, Cranston A, Cole M, Frame S, Buckley CD, Ng WF, Filer A, McInnes IB, Isaacs JD (2020). Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition. Medicine 2020; 99:e20458.

Cole M, Hynes AM, Howel D, Hall L, Abinun M, Allahabadia A, Barrett T, Boelaert K, Drake AJ, Dimitri P, Kirk J, Zammitt N, Pearce S, Cheetham T (2019). Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): Study protocol for a single-arm, single-stage, phase II trial. BMJ Open 2019; 9:e024705.

Parr JR, Todhunter E, Pennington L, Stocken D, Cadwgan J, O'Hare AE, Tuffrey C, Williams J, Cole M, Colver AF (2018). Drooling Reduction Intervention randomised trial (DRI): Comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2018; 103:371-6.

Paleri V, Wood J, Patterson J, Stocken DD, Cole M, Vale L, Franks J, Guerrero-Urbano T, Donnelly R, Barclay S, Rapley T, Rousseau N (2016). A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): Study protocol. Pilot Feasibility Stud 2016; 2:29.

Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV (2016). Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. Eur J Cancer 2016; 55:56-64.

Cole M, Stocken D, Yap C (2015). A pragmatic approach to the design and calibration of a Bayesian CRM dose finding trial. Trials 2015; 16(S2):P210.

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E (2015). PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget 2015; 6:43978-91.

Veal GJ, Hill CR, Cole M, Errington J, Malik G, Boddy AV (2014). Abstract 4651: Characterization of the clinical pharmacokinetics of actinomycin D and the influence of pharmacogenetic variation in children with cancer. Cancer Res 2014; 74:4651.

Fordham SE, Cole M, Irving JA, Allan JM (2014). Abstract 5457: Cytarabine leaves a mutational fingerprint in relapsing leukemia. Cancer Res 2014; 74:5457.

Fordham SE, Cole M, Irving JA, Allan JM (2014). Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia. Leukemia 2015; 29:491-4.

Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ (2014). Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer. Clin Pharmacokinet 2014; 53:741-51.

Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL (2013). Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60:110-7.

Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, Boddy AV, Adamson PC, Barrett JS (2013). Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol 2008; 48:35-42.

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson ADJ, Boddy AV (2012). Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res 2013; 19:469-79.

Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, O'Toole K, Nicholson SL, Bognar L, Garami M, Hauser P, Korshunov A, Pfister SM, Williamson D, Taylor RE, Ellison DW, Bailey S, Clifford SC (2011). MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 2012; 123:501-13.

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M (2011). Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients. Pediatr Blood Cancer 2011; 57:705-897.

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M (2011). Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. Eur J Cancer 2011; 47:1556-63.

Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ (2011). Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 2011; 436:671-9.

Hill RM, Lindsey JC, Megahed H, Schwalbe EC, Cole M, Hogg TL, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC (2011). Abstract 3442: TP53 mutations in favorable risk WNT subtype medulloblastomas. Cancer Res 2011; 71:3442.

Lindsey JC, Hill RM, Megahed H, Lusher ME, Schwalbe EC, Cole M, Hogg TL, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC (2011). TP53 mutations in favorable-risk wnt/wingless-subtype medulloblastomas. J Clin Oncol 2011; 29:e344-6.

See all publications